Valuation: Novartis AG

Market Cap 307B 275B 253B 229B 428B 29,121B 436B 3,013B 1,210B 15,319B 1,151B 1,127B 48,309B P/E 2026 *
23.2x
P/E 2027 * 18.9x
Enterprise Value 341B 306B 281B 255B 476B 32,402B 485B 3,353B 1,346B 17,045B 1,281B 1,253B 53,752B EV / Sales 2026 *
5.95x
EV / Sales 2027 * 5.45x
Free-Float
91.66%
Yield 2026 *
2.69%
Yield 2027 * 2.83%
1 day-0.19%
1 week+6.40%
1 month+12.78%
3 months+2.97%
6 months+8.75%
Current year+16.62%
1 week 152.02
Extreme 152.02
164.06
1 month 139.31
Extreme 139.31
164.06
Current year 135.55
Extreme 135.55
170.46
1 year 122.86
Extreme 122.86
170.46
3 years 92.35
Extreme 92.35
170.46
5 years 74.09
Extreme 74.09
170.46
10 years 66.93
Extreme 66.93
170.46
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Compliance Officer 58 14/04/2025
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%+6.40% - - 307B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.86%+5.90%+46.58%+84.56% 473.55B
Weighted average by Cap. +1.86%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 57.38B 51.39B 47.27B 42.83B 80.07B 5,449B 81.57B 564B 226B 2,866B 215B 211B 9,039B 61.5B 55.08B 50.67B 45.91B 85.81B 5,840B 87.42B 604B 243B 3,072B 231B 226B 9,687B
Net income 13.58B 12.16B 11.19B 10.14B 18.95B 1,290B 19.31B 133B 53.57B 678B 50.97B 49.89B 2,139B 15.99B 14.32B 13.17B 11.94B 22.31B 1,519B 22.73B 157B 63.07B 799B 60.02B 58.74B 2,519B
Net Debt 34.56B 30.95B 28.47B 25.8B 48.22B 3,281B 49.12B 339B 136B 1,726B 130B 127B 5,443B 28.54B 25.56B 23.51B 21.3B 39.82B 2,710B 40.56B 280B 113B 1,425B 107B 105B 4,495B
Projected Income Statement - Annual - Novartis AG
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
30/10/26 USD 160.79 -0.19% 3,152,892
29/10/26 USD 161.10 +3.22% 2,237,115
28/10/26 USD 156.08 -0.50% 1,945,355
27/10/26 USD 156.86 +1.98% 3,734,396
26/10/26 USD 153.81 +1.78% 2,816,388
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Novartis AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
162.39USD
Average target price
153.68USD
Spread / Average Target
-5.37%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Novartis AG